A detailed history of Pacer Advisors, Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 2,372 shares of ALLO stock, worth $5,953. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,372
Previous 3,657 35.14%
Holding current value
$5,953
Previous $16,000 68.75%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.23 - $4.38 $2,865 - $5,628
-1,285 Reduced 35.14%
2,372 $5,000
Q1 2024

May 10, 2024

BUY
$2.92 - $5.63 $10,678 - $20,588
3,657 New
3,657 $16,000
Q2 2021

Jul 21, 2021

SELL
$23.49 - $35.8 $47,637 - $72,602
-2,028 Closed
0 $0
Q1 2021

Apr 05, 2021

SELL
$25.79 - $39.02 $72,263 - $109,334
-2,802 Reduced 58.01%
2,028 $72,000
Q4 2020

Jan 20, 2021

BUY
$25.24 - $43.45 $58,506 - $100,717
2,318 Added 92.28%
4,830 $122,000
Q3 2020

Oct 19, 2020

BUY
$32.38 - $44.96 $81,338 - $112,939
2,512 New
2,512 $95,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $361M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.